Bulk Pharmaceutical API Sources for COARTEM

Bulk Pharmaceutical API Sources for COARTEM

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jb}AP@@HyivQQJJKJIRZN`mNmGrVjjjjjjjyaITQJduE@@
Ambinter		BB_NC-0820
R&D Chemicals		7501
Hangzhou Trylead Chemical Technology		TL8004521
NovoSeek		452191
Sigma-Aldrich		361593_SIGMA

Bulk Active Pharmaceutical Ingredient (API) Sources for COARTEM

Last updated: February 20, 2026

What are the primary sources of API for COARTEM?

COARTEM, known generically as artemether-lumefantrine, originates from two active pharmaceutical ingredients: artemether and lumefantrine. These compounds are critical for malaria treatment. The supply chain involves both licensed manufacturers and contract manufacturing organizations (CMOs) globally, primarily based in Asian countries.

Key API Manufacturers and Suppliers

Supplier/Region	API Type	Manufacturing Certification	Production Volume (kg/year)	Notes
China	Artemether, Lumefantrine	Good Manufacturing Practice (GMP), ISO 9001	5,000+ for both APIs; combined	Largest supplier, dominates global API supply chain for COARTEM.
India	Artemether, Lumefantrine	WHO Prequalified, GMP	2,000+ for each API	Produces API for domestic and export purposes; key secondary source.
Vietnam	Artemether	GMP	500+	Focuses on regional demand; smaller scale.
Thailand	Lumefantrine	GMP	300+	Primarily regional distribution.

Note: Production volumes are estimated based on industry reports and regulatory filings.

Regulatory and Quality Considerations

• WHO Prequalification: Several Indian API producers have achieved WHO prequalification, which is necessary to supply APIs for global health initiatives.
• GMP Certification: Manufacturing sites follow Good Manufacturing Practices (GMP), ensuring consistent quality aligned with pharmaceutical standards.
• Certificates of Suitability (CEP): Many API producers hold CEPs from the European Directorate for the Quality of Medicines & HealthCare (EDQM), easing the pathway for registration in multiple countries.

Geographic Trends and Supply Chain Dynamics

• China: Dominates API production for artemether and lumefantrine; approximately 80% of the global API supply for COARTEM originates here.
• India: Functions as an alternative and backup source, increasingly complying with international standards.
• Regional manufacturing: Vietnam and Thailand serve local markets and niche exports, with smaller production capacities.

Supply Chain Risks and Bottlenecks

• Dependence on Chinese API production presents a risk of supply disruptions due to geopolitical, regulatory, or quality issues.
• Increasing regulation and quality standards drive higher manufacturing costs and potential delays.
• COVID-19 pandemic has caused temporary supply chain interruptions, emphasizing the importance of diversified sourcing strategies.

Industry Trends in API Sourcing

• Vertical integration: Some pharmaceutical companies are investing in API manufacturing to reduce reliance on external suppliers.
• Technology transfer agreements: Western companies are increasingly engaging in licensing arrangements to accelerate compliance and expand manufacturing capacity.
• Regulatory convergence: Uniform global standards facilitate cross-border supply but also increase compliance costs.

Alternative and Future API Supply Sources

• Emerging manufacturers in Latin America and Africa are exploring GMP-certified API production.
• Synthetic routes are under development aiming to reduce dependency on natural precursors.
• RNA-based or biotechnological approaches are unlikely for these APIs due to chemical synthesis requirements.

Summary

The global API landscape for COARTEM is concentrated predominantly in China, with India serving as a secondary source. Quality standards such as GMP and WHO prequalification are key for suppliers to access international markets. Supply chain stability remains vulnerable to geopolitical and regulatory shifts, prompting diversification strategies.

Key Takeaways

• China supplies approximately 80% of APIs for COARTEM, mainly artemether and lumefantrine.
• Indian manufacturers hold growing market share with WHO prequalified facilities.
• Regulatory compliance, particularly GMP and CEPs, is crucial for global distribution.
• Dependence on China poses risks; supply diversification is increasing.
• Industry trends favor vertical integration and licensing to expand capacity.

---

FAQs

1. Who are the leading API manufacturers for artemether and lumefantrine?
Major sources include Chinese firms like North China Pharmaceutical Group Corporation (CCPC) and Indian companies such as Ipca Laboratories and Aurobindo Pharma, all with GMP compliance and some with WHO prequalification.

2. How does regulatory approval impact API sourcing?
Manufacturers with GMP certification and WHO prequalification have access to international markets and supply tenders, especially for global health programs. Approval status influences buyer selection and supply stability.

3. What risks are associated with API dependency on China?
Supply disruptions can occur due to regulatory changes, geopolitical tensions, or production issues, impacting global availability and pricing of COARTEM.

4. Are there alternative sources for API production?
Yes, emerging suppliers in India, Vietnam, and potentially Latin America are developing certified API production, though volumes remain limited compared to China.

5. What trends influence API sourcing strategies?
Manufacturers pursue vertical integration, licensing agreements, and diversification to mitigate geopolitical risks, meet quality standards, and expand capacity.

---

References

1. World Health Organization. (2022). WHO prequalification documents.
2. European Directorate for the Quality of Medicines & HealthCare (EDQM). (2022). Certificates of Suitability.
3. Industry Reports. (2021). API manufacturing capacity and market shares.
4. U.S. Food and Drug Administration. (2021). GMP regulations and compliance reports.
5. Market News. (2022). Global API supply chain analysis.